Poly(ADP-ribose) polymerase 1 at the crossroad of metabolic stress





































Aging is a multi-factorial process defined as time-
dependent general decline in physiological function, 
which is associated with a progressively increasing risk 
of frailty, morbidity and mortality [1, 2]. The effect of 
aging is mainly observed in modern human societies 
and in animals under laboratory conditions [3]. The 
dramatic increase in mean human life span and life 
expectancy, coupled to a significant reduction in early 
mortality caused by the reduced occurrence of 
infections during the past two centuries, has led to an 
enormous increase in the number of elderly people in 
modern societies [4, 5]. This demographic phenomenon 
has been paralleled by an epidemic of chronic diseases 
associated with advanced age, most of which have 
complex etiology and underlying pathogenic mecha-







































































decades to identify single key players involved in age-
related diseases. Poly(ADP-ribose) polymerase 1 
(PARP1) is a chromatin-associated nuclear protein which 
functions as stress sensor and as such is involved in the 
cellular responses to a variety of age-related stress 
signals.  
 
Poly(ADP-ribose) polymerase 1 as molecular stress 
sensor 
 
PARP1 is an abundant nuclear chromatin-associated 
multifunctional enzyme found in most eukaryotes apart 
from yeast [7]. PARP1 has been initially thought to be 
the only existing enzyme with poly(ADP-ribosyl)ation 
activity in mammalian cells. However, five additional 
Parp-like genes encoding “bona fide” PARP enzymes 
have been identified in recent years, indicating that 
PARP1 belongs to a family of “bona fide” PARP 
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very low, but is stimulated dramatically under conditions 
of cellular stress [9, 10]. Activation of PARP1 results in 
the synthesis of poly(ADP-ribose) (PAR) from 
nicotinamide adenine dinucleotide (NAD
+) and in the 
release of nicotinamide as reaction by-product [7, 8]. 
Following PARP1 activation, intracellular PAR levels 
can rise 10–500-fold [11-13]. Despite intensive research 
on the cellular functions of PARP1, the molecular 
mechanism of PAR formation has not been comprehen-
sively understood. Up to now, two different modes of 
PARP1 activation have been described, one dependent on 
DNA damage and one dependent on post-translational 
protein modifications (see below).  
 
PAR is a heterogeneous linear or branched homo-
polymer of repeating ADP-ribose units linked by 
glycosidic ribose-ribose bonds [7, 9, 14]. Most free or 
protein-associated PAR molecules are rapidly degraded 
in vivo [15]. This rapid turnover strongly suggests that 
PAR levels are tightly regulated under physiological 
stress conditions and that degradation of the polymer 
starts immediately upon initiation of PAR synthesis. To 
date two enzymes, poly(ADP-ribose) glycohydrolase 
(PARG) and ADP-ribosyl protein lyase, have been 
described to be involved in PAR catabolism [16, 17]. 
While PARG possesses both exo- and endoglycosidic 
activities, the lyase has been described to cleave the 
bond between proteins and mono(ADP-ribose). The 
attachment of negatively charged PAR onto proteins is 
transient but can be very extensive in vivo, as polymer 
chains can reach more than 400 units on protein 
acceptors [7]. PAR formation has been implicated in a 
variety of cellular processes, such as maintenance of 
genomic stability, transcriptional regulation, energy 
metabolism and cell death [7]. The physiological 
consequences of this post-translational modification on 
the molecular level, however, are not yet completely 
understood. It has been proposed that PAR may have a 
dual role in modulating cell survival and cell death [9, 
18, 19]. Low to moderate levels of PAR may be 
beneficial for important cellular functions, whereas 
extensive PAR formation can be detrimental and lead to 
various forms of cell death. More than a decade ago, 
PARP1 activity was linked to the aging process, as 
poly(ADP-ribosyl)ation capacity was shown to correlate 
with species-specific longevity [20, 21].  
 
Most proteins associated with PAR are nuclear DNA-
binding proteins, including PARP family members and 
histones [7, 22, 23]. PARP1 is the main acceptor for 
poly(ADP-ribosyl)ation  in vivo and auto-modification 
of PARP1 abolishes its affinity for NAD
+ and DNA [24, 
25]. A similar effect has been postulated for 
histones/nucleosomes. PAR polymers could function to 
alter chromatin conformation through covalent or non-
covalent interactions with histone tails and via 
displacement of histones from DNA, thus regulating the 
accessibility of the genetic material. It was suggested 
that PAR might either directly participate in chromatin 
remodelling processes or indirectly coordinate them 
through recruitment and regulation of specific 
chromatin remodelling proteins [7, 22]. Moreover, PAR 
is recognized and bound by macrodomain containing 
histone variants [26].  
 
Over 20 years ago, Nathan Berger was the first to 
suggest that cellular stress (e.g. oxidative damage) 
causes over-activation of PARP1 and subsequent NAD
+ 
depletion [27, 28]. In an attempt to restore the NAD
+ 
pools, NAD
+ is resynthesized with a consumption of 2-4 
molecules of ATP per molecule of NAD
+. As a 
consequence, cellular ATP levels become depleted, 
leading to subsequent energy failure, which results in 
cellular dysfunction and eventually in necrotic cell 
death [27, 28]. Pharmacological inhibition of the 
enzymatic activity of PARP or the complete absence of 
PARP1 was shown to significantly improve cellular 
energetic status and cell viability after exposure to 
necrosis-inducing agents [29-31]. The contribution of 
poly(ADP-ribosyl)ation reactions to necrotic cell death 
seems to be dependent on the cell type and the cellular 
metabolic status [7, 32, 33].  
 
Interestingly, genetic studies using Parp1  knockout 
mice provided preliminary evidence that energy 
depletion alone might not be sufficient to mediate 
poly(ADP-ribosyl)ation-dependent cell death [34]. A 
second model has been proposed to explain how PARP1 
regulates cell death. This model suggests that over-
activation of PARP1 induces translocation of apoptosis-
inducing factor (AIF) from the mitochondria to the 
nucleus, causing DNA condensation and fragmentation, 
and subsequent cell death [35]. 
 
Together, PARP1 can be regarded as molecular stress 
sensor with many physiological cellular functions. 
Over-activation of PARP1 results in the generation of 
large amounts of PAR. Subsequently, cellular NAD
+ 
pools are depleted and AIF is released from the 
mitochondria to trigger cell death. Importantly, these 
PARP1-dependent cellular suicide mechanisms have 
been implicated in the pathomechanisms of neuro-
degenerative disorders, cardiovascular dysfunction and 
various other forms of inflammation [36]. 
  
Activation of PARP1 by reactive oxygen species (ROS)  
 
A unified theory explaining the pathogenesis of diverse 
degenerative conditions in different organs (including 
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disorders, rheumatoid arthritis, atherosclerosis and other 
cardiovascular diseases, diabetes) has been proposed to 
explain how the single physiological process of aging 
may lead to diverse pathological states [37]. This 
oxidative stress theory of aging (or free radical theory 
of aging), initially proposed by Harman in 1956, 
provides the most plausible and currently acceptable 
global mechanism to explain the aging process [38]. 
The theory postulates that aging is, in the absence of 
other risk factors (e.g. infections, smoking, 
hypercholesterolemia), the net consequence of free 
radical-induced damage and the inability to counter-
balance these changes by anti-oxidative defenses. An 
increase in intracellular ROS levels through hydrogen 
peroxide treatment of cells or through the inhibition of 
ROS scavenging enzymes, such as superoxide 
dismutase (SOD1), causes premature senescence and 
can shorten cellular life span [39-45]. Mitochondria are 
the main producers of cellular ROS under normal 
conditions, as approximately 1-2% of the oxygen 
molecules consumed during respiration are converted 
into highly reactive superoxide anions [46]. Besides 
aerobic metabolism in mitochondria, β-oxidation in 
peroxisomes and certain enzymes can produce ROS. 
Intracellular ROS can damage cellular components 
through oxidation of macromolecules such as nucleic 
acids, proteins and lipids [47]. Moreover, an 
overproduction of ROS leads to rapid generation of 
peroxinitrite from nitric oxide and superoxide, causing 
an imbalance in nitric oxide signaling [48].  
 
Since the oxidative stress theory was first proposed, a 
considerable body of evidence has been published 
corroborating the idea that increased production of ROS 
underlies cellular dysfunction in various organ systems 
of aged humans and laboratory animals [49]. 
Interestingly, the enzymatic activity of PARP1 can be 
strongly activated by treatment of cells with ROS such 
as hydrogen peroxide [8]. Earlier studies described that 
PARP1 binds to oxidative damage-induced strand 
breaks within the DNA via two zinc finger motifs and 
thereby becomes activated [9]. More recently, several 
studies suggested that PARP1 activity is also regulated 
in a DNA-independent manner. A proteomic investiga-
tion uncovered many ERK1/2-induced phosphorylation 
sites in PARP1, which are located within important 
functional domains, consistent with regulatory roles in 
vivo [50, 51]. Furthermore, DNA-independent PARP1 
activation can be triggered by the direct interaction of 
PARP1 with phosphorylated ERK-2 without PARP1 
being phosphorylated itself [52].  In addition, PARP1 
can be activated by elevated levels of extracellular 
glucose, Ca
2+ and angiotensin II, and allosteric 
regulation of auto-poly(ADP-ribosyl)ation by Mg
2+, 
Ca
2+, polyamines, ATP and the histones H1 and H3 has 
been reported [53]. Whether ROS-mediated activation 
of PARP1 is due to ROS-generated DNA damage or 
also based on other ROS-induced cellular (signaling) 
mechanisms awaits further investigations. 
 





+ biosynthesis has become of considerable interest 
due to the important signaling functions of pyridine 
nucleotides. In mammals, niacin (collectively 
designating nicotinamide and nicotinic acid) and the 
essential amino acid tryptophan are precursors of NAD
+ 
biosynthesis [12, 54]. The formation of dinucleotides 
from ATP and the mononucleotide of niacin constitute 
the most critical step in NAD
+  generation, which is 
catalyzed by NMN/NaMN adenylyltransferases 
(NMNATs) [13, 55]. Since PARP1 uses NAD
+ as 
substrate to synthesize PAR, PARP1 decisively depends 
on the amount of NAD
+ available and may act as energy 
sensor in the nucleus. Both constitutive and activated 
levels of PAR have been suggested to be strictly 
dependent on the concentration of NAD
+ in cells [15, 
56, 57]. Importantly, the nuclear concentration of NAD
+ 
can be modulated by NMNAT-1 and a recent study 
revealed that NMNAT-1 is able to interact with and 
stimulate PARP1 [58]. It is thus tempting to speculate 
that PARP1 activation is supported by the localized 
action of NMNAT-1. Depending on the level of PARP1 
activity, the cellular NAD
+ concentration is 
concomitantly reduced. Therefore, PARP1 not only is a 
sensor of NAD
+, but in turn also influences cellular 
energy levels. 
 
Dietary restriction, also called calorie restriction, is 
defined as a life-long moderate (20-40%) reduction in 
caloric intake and has repeatedly been shown to extend 
the longevity of both invertebrates and vertebrates [59, 
60]. Reducing the caloric intake starting even at an old 
age has also been shown to increase the life span of flies 
and mice and is sufficient to reverse gene expression 
changes associated with aging [61-63]. Furthermore, 
dietary restriction in rodents delays the onset and 
reduces the severity of many age-related diseases, such 
as cardiovascular disease, diabetes, osteoporosis, 
cataracts, neurodegenerative disease and cancers [60]. 
Although it was initially expected that dietary 
restriction would reduce overall cellular energy levels 
by slowing down glycolysis and the tricarboxylic acid 
(TCA) cycle [59], this assumption has been challenged, 
since dietary restriction was shown to cause an increase 
in NAD
+/NADH ratios in yeast cultures [64]. Whether 
this is also the case in mammalian cells remains to be 
determined. Along the same lines, the impact of dietary 
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PARP1) is currently being investigated in multiple 
laboratories. Whether and how PARP1 activation 
differs in species with different maximal life span (and 
possibly also with different cellular NAD
+ pools), 
however, remains an open question. 
 





+ is an essential cofactor regulating numerous 
cellular pathways and has recently been recognized as a 
substrate for a growing number of NAD
+-dependent 
enzymes [11, 13]. NAD
+-dependent post-translational 
protein modifications are catalyzed by several enzyme 
families, including PARPs and the sirtuin family of 
NAD
+-dependent class III histone deacetylases (SIRTs) 
[8, 65, 66]. SIRTs and the yeast homolog and founding 
member of the sirtuins, Sir2, are induced by dietary 
restriction and have been implicated in senescence and 
aging, although the exact mechanisms are not yet 
known [59, 67]. Intriguingly, ADP-ribosylation by 
PARP1 could modulate the NAD
+-dependent 
deacetylation of proteins by SIRTs via the 
NAD
+/nicotinamide connection. The decline of NAD
+ 
levels and the rise of nicotinamide upon PARP1 
activation have immediate effects on other NAD
+-
consuming enzymes [57, 68, 69]. SIRTs require NAD
+ 
as substrate and are inhibited by low levels of 
nicotinamide [70]. Consequently, under conditions of 
cellular stress and PARP1 activation, the activity of 
SIRTs is downregulated. 
 
PARPs and sirtuins may not only compete for the same 
substrate, but might also regulate each other more 
directly. For instance, PARP1 and SIRT1 interact at the 
protein level and SIRT1 might be regulated by PARP1-
dependent trans-ADP-ribosylation [7]. Another link 
between PAR generation and acetylation/deacetylation 
reactions comes from the very recent identification of 
three lysine residues in the auto-modification domain of 
PARP1 as acceptor sites for auto-ADP-ribosylation 
[71]. The same lysines were previously identified as 
targets for acetylation by p300 and PCAF [72]. 
Remarkably, simple addition of PCAF reduced 
poly(ADP-ribosyl)ation of PARP1 (own unpublished 
observation), suggesting that the interaction domain of 
PARP1 with PCAF is overlapping with the ADP-ribose 
acceptor sites. We recently also published that 
acetylation of lysine residues interferes with ADP-
ribosylation [73]. This finding points at an interesting 
crosstalk between acetylation of and ADP-ribosylation 
by PARP family members. It will certainly be 
interesting to further investigate the crosstalk between 
PARP1-dependent  ADP-ribosylation  and acetylation/ 
deacetylation reactions. NAD
+ levels can be expected to 
play an important role for the interplay between these 
two NAD
+-dependent post-translational protein 
modifications. Whether the balance between and the 
tight regulation of poly(ADP-ribosyl)ation and NAD
+-
dependent deacetylation is altered during aging remains 
to be investigated. Furthermore, it will be important to 
identify additional NAD
+-dependent enzymes involved 
in the aging process.  
 
Emerging pathological evidence indicates that major 
chronic age-related diseases, such as atherosclerosis, 
arthritis, dementia, osteoporosis and cardiovascular 
disease, are inflammation-related [74]. A link between 
NAD
+ metabolism and the regulation of an 
inflammatory response is suggested by the finding that 
nicotinamide phosphoribosyltransferase (NAMPT), one 
of the enzymes involved in NAD
+ biosynthesis from 
nicotinamide, increases cellular NAD
+  levels in 
response to stress [75]. The expression of NAMPT is 
upregulated in activated lymphocytes [76]. 
Furthermore, NAMPT protein and/or mRNA levels 
were also found to be upregulated upon stimulation of 
immune cells both in vivo and in vitro [77, 78], whereas 
a specific NAMPT inhibitor was found to inhibit 
cytokine production [79].  Notably, nicotinamide is 
known to inhibit the production of key inflammatory 
mediators [80-82], protects neurons against 
excitotoxicity [83, 84], and blocks replicative 
senescence of primary cells [85]. Moreover, a recent 
study suggested that intracellular NAD
+ levels regulate 
TNF-α protein synthesis in a SIRT6-dependent manner 
[86].  Both, SIRT1 and SIRT6 also regulate NF-κB 
signaling with effects on senescence and possibly aging 
[87, 88]. 
 
Together, accumulating evidence suggests that cellular 
NAD
+ biosynthesis and the NAD
+-consuming reactions 
poly(ADP-ribosyl)ation and SIRT-dependent 
deacetylation are tightly interrelated and have functions 
in inflammation and age-related diseases. 
 
PARP1 is linked to age-related inflammation as 
transcriptional cofactor of NF-κB 
 
A body of experimental and clinical evidence suggests 
that the immune system is implicated in almost all age-
related or associated diseases [89, 90]. There is a well-
established connection between oxidative stress and the 
inflammatory immune response [37]. A prominent 
mechanism by which age-induced ROS modulate 
inflammation is by inducing the redox-sensitive 
transcription factor nuclear factor kappa B (NF-κB). 
This induction of NF-κB leads to the generation of pro-
inflammatory mediators and a state of chronic 
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in inflammatory phenotypic changes in various 
pathophysiological conditions [49]. In fact, NF-κB has a 
fundamental role in mediating all the classical attributes 
of inflammation – rubor, calor, dolor and tumor – by 
regulating transcriptional programs in tissues containing 
epithelial and stromal cells, vascular endothelial cells 
and hematopoietic cells [93]. During the last decade, it 
has been clearly demonstrated that excessive activation 
or inappropriate regulation of immune and inflam-
mation cascades causes tissue and cellular damage, 
which can lead to cellular dysfunction and death [14]. 
Furthermore, it was suggested that chronic, low-grade 
inflammation is a possible converging process linking 
normal aging and the pathogenesis of age-related 
diseases [94]. This hypothesis is in accordance with the 
finding that constitutive activation of NF-κB, 
accompanied by elevated levels of inflammatory 
markers, is a ubiquitous phenomenon observed in 
various cell types in the aging phenotype [95].  
 
In most unstimulated cells, NF-κB is sequestered in the 
cytoplasm as an inactive transcription factor complex 
by its physical association with one of several inhibitors 
of NF-κB (IκB) [96-100]. The key regulatory event in 
NF-κB induction is the phosphorylation of IκB proteins 
by the IκB kinase (IKK) complex, which leads to IκB 
protein ubiquitylation and subsequent degradation [101, 
102]. ROS have been reported to induce the activation 
of NIK/IKK and MAPK pathways that lead to the 
degradation of IκB and subsequent NF-κB-dependent 
gene expression [74, 103]. Conversely, induction of NF-
κB itself results in the generation of ROS via the 
expression of inducible nitric oxide synthase (iNOS), 
thus activating a feedback loop that amplifies the 
process of damage and deterioration in target cells and 
organs [37]. 
 
Global screens for age-specific gene regulation have 
been performed from many tissues in mice and humans 
[3]. These analyses have recently provided evidence 
that the NF-κB binding domain is the genetic regulatory 
motif most strongly associated with the aging process 
and that NF-κB target genes show a strong increase in 
expression with age in human and mouse tissues as well 
as in stem cells [104-106]. Furthermore, NF-κB is 
implicated in age-dependent induction of cellular 
senescence in epithelial and hematopoietic progenitor 
cells [104, 107]. Blockade of NF-κB in the skin of aged 
mice can reverse the global gene expression program 
and tissue characteristics to that of younger animals 
[108]. Moreover, Donato et al. reported lately that in 
vascular endothelial cells of aged human donors nuclear 
NF-κB levels increase, IκBα levels decrease and that 
the expression of proinflammatory cytokines, such as 
interleukin 6 (IL-6), tumor necrosis factor-α (TNF-α) 
and monocyte chemoattractant protein 1 (MCP-1) is 
reduced [109]. NF-κB activity was also increased in 
aged rat vessels and kidneys, but reduced in rats under 
calorie restriction [110, 111]. 
 
Studies performed with Parp1 knockout mice have 
identified various detrimental functions of PARP1 in 
inflammatory and neurodegenerative disorders. Parp1 
gene-disruption protected from tissue injury in various 
oxidative stress-related disease models ranging from 
stroke, (MPTP)-induced parkinsonism, myocardial 
infarction, streptozotocin-induced diabetes, lipo-
polysaccharide-induced septic shock, arthritis, to colitis 
and zymosan-induced multiple organ failure [7, 73, 112, 
113]. There are striking similarities between the 
expression pattern of PARP1 and the detrimental 
transcriptional activity of NF-κB. In most tissues and 
cell types associated with high PARP1 expression, 
dysregulated NF-κB activity seems to contribute to 
cellular dysfunction and necrotic cell death during 
inflammatory disorders [14]. The strongest indication 
for a direct role of PARP1 in NF-κB-dependent 
transcription was the impaired expression of NF-κB-
dependent pro-inflammatory mediators in Parp1 
knockout mice [113]. Moreover, the upregulation of 
several inflammatory response genes after treatment 
with inflammatory stimuli was drastically reduced in 
Parp1 knockout mice [112, 114-116]. Our group 
provided first evidence that PARP1 is required for 
specific NF-κB-dependent gene activation and can act 
as transcriptional coactivator of NF-κB in vivo [117]. 
PARP1 is required and sufficient for specific 
transcriptional activation of NF-κB in response to pro-
inflammatory stimuli and cellular stress. Furthermore, 
Tulin and Spradling found that Drosophila mutants 
lacking normal PARP levels display immune defects 
similar to mice lacking the NF-κB subunit p50 [118].
 
These results imply that the role of PARP1 in NF-κB-
dependent gene expression during immune responses 
has been conserved during evolution. Together, several 
lines of evidence suggest a model in which PARP1 
functions as a promoter-specific cofactor for NF-κB-
dependent gene expression [7, 14].  
 
PARP as therapeutic target for age-associated 
diseases 
 
During the last two decades of intensive research, over 
50 potential PARP inhibitors were developed [119]. The 
involvement of PARP1 in cell death (both apoptosis and 
necrosis) and the capacity of PARP1 to promote the 
transcription of pro-inflammatory genes are particularly 
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structural information available for the catalytic 
domains of PARP1 and PARP2 co-crystallized with 
NAD
+ or certain PARP inhibitors, it became clear that 
the majority of PARP inhibitors mimic the nicotinamide 
moiety of NAD
+ and bind to the donor site within the 
catalytic domain [120-122]. Although the physiological 
functions of PARPs and poly(ADP-ribosyl)ation is still 
under debate, numerous experimental studies during the 
last years have clearly demonstrated the beneficial 
effects of PARP inhibition from cell culture systems to 
pre-clinical animal models of acute and chronic 
inflammation [36, 119]. For instance, Vaziri and 
colleagues observed an extension of cellular life span 
when PARP activity was inhibited [123]. In animal 
studies, PARP inhibition and/or PARP1 deficiency is 
effective in different age-related diseases [119]. The 
PARP inhibitor 5-AIQ has been demonstrated to 
attenuate the expression of P-selectin and intracellular 
adhesion molecule-1 (ICAM-1) as well as the 
recruitment of neutrophils and leukocytes into the 
injured lung [124, 125]. Thus, application of inhibitors 
reduces the degree of acute inflammation and tissue 
damage associated with experimental lung injury. As 
ROS released from the recruited leukocytes cause an 
upregulation of adhesion molecules, treatment with 
PARP inhibitors contributes to the termination of this 
vicious cycle and inhibits the inflammatory process. 
Similar to the effects of pharmacological inhibitors, 
Parp1 knockout mice were found to be resistant against 
zymosan-induced inflammation and multiple organ 
failure when compared with the response of wild-type 
animals [126]. 
 
In murine models of arthritis, inhibition of PARP with 
nicotinamide delayed the onset of the disease and 
reduced the progress of established collagen-induced 
arthritis [127]. 5-iodo-6-amino-1,2-benzopyrone and 
PJ34, two novel PARP inhibitors, were beneficial in a 
mouse model of collagen-induced arthritis by reducing 
both the incidence of arthritis and the severity of the 
disease [128, 129]. Similarly, GPI 6150 was found to be 
highly effective in a rodent model of adjuvant-induced 
arthritis [130]. 
 
PARP activation also has a pathogenic role in 
hypertension, atherosclerosis and diabetic 
cardiovascular complications [119, 131]. In these 
diseases, the function of the vascular endothelium is 
impaired, resulting in a reduced ability of the 
endothelial cells to produce nitric oxide and other 
cytoprotective mediators. This then sets the stage for 
many manifestations of cardiovascular disease. The 
oxidant-mediated endothelial cell injury is dependent on 
PARP1 and can be attenuated by pharmacological 
inhibitors or genetic PARP1 deficiency [115, 132]. 
Furthermore, PARP inhibition improves aging-
associated cardiac and endothelial dysfunction [133]. 
 
In general, the severity of many inflammatory diseases 
is suppressed by PARP inhibitors and the production of 
multiple pro-inflammatory mediators is downregulated 
[48]. The inhibition of PARP also reduces the formation 
of nitrotyrosine in inflamed tissues, an indicator of 
reactive nitrogen species. This finding was, at first, 
unexpected because PARP activation is perceived to 
occur downstream of the generation of oxidants and free 
radicals in various diseases. The mechanism is probably 
related to the fact that PARP inhibition reduces the 
infiltration of neutrophils into inflammatory sites [126]. 
This in turn reduces oxygen- and nitrogen-centered 
free-radical production. The basis for the regulation of 
neutrophil infiltration by PARP might be related to the 
reduced expression of adhesion molecules [134, 135] 
and/or the preservation of endothelial integrity [115, 
132]. Alternatively, the reduction of nitrotyrosine could 
be explained by the finding that PARP1 is required for 
the expression of iNOS, the main producer of nitric 
oxide in inflamed tissues [116]. In summary, multiple 
studies suggest that a tight regulation of PARP activity 
is required to prevent a variety of age-related 
pathological conditions. 
 
Role of PARP1’s enzymatic activity in NF-κB -
dependent gene expression  
 
There is no consensus in the literature as to whether the 
modulation of NF-κB-mediated transcription by PARP1 
is dependent on poly(ADP-ribosyl)ation or, alterna-
tively, merely on the physical presence of PARP1 [14]. 
Genetic approaches provide strong evidence that 
poly(ADP-ribosyl)ation is not affecting the DNA 
binding activity of NF-κB and is not required for NF-
κB-dependent gene expression [14, 136].
  Neither the 
enzymatic activity of PARP1 nor its binding to DNA 
was required for full activation of NF-κB in response to 
various stimuli in vivo when tested on transiently 
transfected reporter plasmids [137, 138]. Consistently, 
the enzymatic activity of PARP1 was not required for 
full transcriptional activation of NF-κB in the presence 
of the histone acetyltransferase p300 [72]. At first 
glance this seems not to be compatible with reports 
describing that PARP inhibitors abolish mRNA 
expression of iNOS, IL-6 and TNF-α in cultured cells 
[139] or that PARP inhibitors reduce the expression of 
inflammatory mediators in mice [124, 126, 140]. 
However, this discrepancy might be explained in three 
ways: First, it should be noted that the currently 
available PARP inhibitors do not discriminate well 
between PARP1 and other PARP family members or 
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described to also play a role in inflammatory response 
pathways [139, 141].
  In  Parp1 knockout mice, PAR 
formation is indeed drastically reduced only in brain, 
pancreas, liver, small intestine, colon, and testis, 
whereas still moderate  levels of residual poly(ADP-
ribose) formation can be observed in the stomach, 
bladder, thymus, heart, lung, kidney and spleen [7]. 
This residual activity can most likely be attributed to 
PARP2, which has the greatest similarity to PARP1 
among all PARP family members [8]. Interestingly, 
PARP2 is involved in T lymphocyte development and 
survival [142] and has been implicated in inflammatory 
immune responses [143, 144].
 A putative role of PARP2 









































recent reports, one cannot exclude the possibility that 
PARP-inhibitors might even affect non-NAD
+-
consuming targets such as AKT/PKB or MMPs [145]. 
Third, the enzymatic activity of PARP1 might be 
required for the transcriptional activity of transcription 
factors involved in inflammatory processes other than 
NF-κB. Several groups have shown that co-operative 
activities between transcription factors such as AP-1, 
STAT-1 or IRF-1 in the enhanceosomes of NF-κB 
dependent genes are required for full synergistic 
activation of target genes [146, 147]. Considering these  
constraints of all currently available PARP inhibitors, 
the specific contribution of PARP1 enzymatic activity 
for age-related diseases, in which PARP inhibition has 












































PARP1  senses  energy  levels  and  crosstalks  with  other  NAD
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Several publications in the past years indicate that the 
nuclear protein PARP1 represents a molecular link 
between energy metabolism and inflammation (Figure). 
As NAD
+-consuming enzyme, PARP1 acts as nutrient 
or energy sensor, crosstalks with other NAD
+-
consuming enzymes (such as sirtuins) and modulates 
(as regulator of NF-κB-dependent transcription of 
cytokines) inflammatory responses. Thus, PARP1 
seems to be an ideal candidate to integrate metabolic 
and inflammatory signals, which arise during the 
process of aging. As central integrator, PARP1 may 
mediate cellular stress response pathways and thereby 
participate in a multitude of age-related pathologies. 
PARP inhibition has proven beneficial in many cell 
culture and animal model systems of acute and chronic 
inflammation and age-related diseases. Clearly, addi-
tional research will further improve our understanding 
of the functions of PARP1 and their implications in age-
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